ArticleThe oncologist2018

Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.

Nadia Harbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.